Uncategorized

Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity

Kinarus Therapeutics Holding AG announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian Investment Management Co, in Kinarus.

Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity Read More »

Coherus BioSciences Announces New Employment Inducement Grants – June 27, 2023

Coherus BioSciences, Inc., announced that effective June 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 48,000 shares of the common stock of the Company to six newly hired employees with a per share exercise price of $3.84, the closing trading price on the grant date.

Coherus BioSciences Announces New Employment Inducement Grants – June 27, 2023 Read More »

Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody

The primary endpoint was met in a Phase 2b study of amlitelimab in adults with moderate-to-severe atopic dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical medications are not a recommended treatment approach.

Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody Read More »

Scroll to Top